Vertex Pharmaceuticals Incorporated (VRTX)

NASDAQ: VRTX · Real-Time Price · USD

515.44

+0.88 (0.17%)

At close: Sep 11, 2026, 4:00 PM EDT

514.51

-0.93 (-0.18%)

After-hours: Sep 11, 2026, 7:30 PM EDT

Vertex Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 11, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	130,644	115,026	103,707	104,849	74,127	55,834
Market Cap Growth	31.14%	10.91%	-1.09%	41.44%	32.76%	-9.15%
Enterprise Value	118,980	104,851	94,253	91,965	65,181	49,750
Last Close Price	515.44	453.36	402.70	406.89	288.78	219.60

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 11, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	30.00	29.10	-	28.97	22.31	23.84
Forward PE	41.55	22.61	22.66	24.44	18.83	16.42
PS Ratio	10.38	9.58	9.41	10.62	8.30	7.37
PB Ratio	6.45	6.16	6.32	5.96	5.33	5.53
P/TBV Ratio	6.97	6.71	7.15	6.70	6.07	6.42
P/FCF Ratio	34.42	36.02	-	31.42	18.89	23.18
P/OCF Ratio	30.43	31.68	-	29.64	17.95	21.12
PEG Ratio	3.11	0.15	1.21	1.92	0.58	1.62

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 11, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
EV/Sales Ratio	9.45	8.74	8.55	9.32	7.30	6.57
EV/EBITDA Ratio	23.33	21.55	20.59	20.54	14.40	12.38
EV/EBIT Ratio	24.23	22.37	21.45	21.35	14.89	12.78
EV/FCF Ratio	31.34	32.83	-	27.56	16.61	20.66

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 11, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Debt / Equity Ratio	0.10	0.11	0.11	0.05	0.07	0.10
Debt / EBITDA Ratio	0.37	0.40	0.37	0.18	0.20	0.24
Debt / FCF Ratio	0.52	0.64	-	0.24	0.23	0.40
Net Debt / Equity Ratio	-0.58	-0.55	-0.58	-0.73	-0.72	-0.65
Net Debt / EBITDA Ratio	-2.29	-2.11	-2.07	-2.88	-2.21	-1.63
Net Debt / FCF Ratio	-3.07	-3.22	11.99	-3.87	-2.54	-2.72
Asset Turnover	0.49	0.50	0.49	0.48	0.57	0.60
Inventory Turnover	3.47	3.85	5.31	7.38	8.87	8.97
Quick Ratio	2.54	2.24	2.17	3.60	4.46	4.04
Current Ratio	3.19	2.90	2.69	3.99	4.83	4.46
Return on Equity (ROE)	23.54%	22.54%	-3.15%	22.99%	27.67%	24.93%
Return on Assets (ROA)	11.93%	12.16%	12.14%	13.17%	17.33%	19.32%
Return on Invested Capital (ROIC)	28.80%	30.54%	-98.60%	63.54%	90.72%	102.53%
Return on Capital Employed (ROCE)	20.90%	21.50%	23.20%	22.50%	28.40%	34.50%

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 11, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Earnings Yield	3.37%	3.44%	-0.52%	3.45%	4.48%	4.20%
FCF Yield	2.91%	2.78%	-0.76%	3.18%	5.29%	4.31%
Buyback Yield / Dilution	0.85%	-0.04%	1.00%	-0.54%	0.31%	1.33%

SEC Filings: 10-K · 10-Q